| Literature DB >> 35501805 |
Han Cui1,2, Ruirui Duan3, Hongtao Niu4, Tao Yu4, Ke Huang4, Chen Chen4, Ke Hao5, Ting Yang6,7,8, Chen Wang9,10,11,12.
Abstract
BACKGROUND: Bronchial asthma is a heterogeneous disease with distinct disease phenotypes and underlying pathophysiological mechanisms. Long non-coding RNAs (lncRNAs) are involved in numerous functionally different biological and physiological processes. The aim of this study was to identify differentially expressed lncRNAs and mRNAs in patients with asthma and further explore the functions and interactions between lncRNAs and mRNAs.Entities:
Keywords: Bronchial asthma; Long non-coding RNA; Microarray analysis; Peripheral blood mononuclear cell; mRNA
Mesh:
Substances:
Year: 2022 PMID: 35501805 PMCID: PMC9059365 DOI: 10.1186/s12890-022-01945-9
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.320
Baseline characteristics of the study participants
| Characteristics | Asthma (n = 10) | Control (n = 9) |
|---|---|---|
| Age (years) | 33.5 (28.8, 38.0) | 35 (34, 38) |
| Gender (male, %) | 50.0 | 55.5 |
| Body mass index (BMI, kg/m2) | 23.6 (21.6, 25.7) | 23.7 (21.3, 25.8) |
| Pulse oximetry saturation (SpO2, %) | 97.0 ( 96.0, 97.3) | 99.0 (98.5, 99.0)*** |
| Current/ex-smoker | 1 | 0 |
| Blood white blood cells count (cells/μL) | 5300.0 (4700, 7400) | 5770.0 (5130.0, 7370) |
| Blood eosinophils count (cells/μL) | 150.0 (135, 220) | 290 (180.0, 415) |
| Blood eosinophils (%) | 4.0 (2.5, 4.5) | 4.0 (3.2, 8.5) |
| Blood basophils (%) | 0.0 (0.0, 0.2) | 0.4 (0.4, 0.8)** |
| Blood neutrophils (%) | 62.8 (58.6, 66.9) | 59.0 (57.3, 60.9) |
| Blood lymphocytes (%) | 28.6 (26.4, 35.6) | 28.3 (26.9, 32.7) |
| Blood monocytes (%) | 4.0 (2.5, 4.5) | 5.2 (3.2, 5.7) |
| Forced expiratory volume in 1 s (FEV1, L) | 3.1 (2.8, 3.6) | 3.3 (2.7, 3.7) |
| FEV1% pred (%) | 84.4 (74.8, 102.4) | 96.0 (92.5, 103.5) |
| FEV1/forced vital capacity (FVC) (%) | 84.4 (74.8, 102.4) | 83.4 (77.7, 88.2) |
| Fractional exhaled nitric oxide (FeNO, bbp) | 72.0 (23.0, 128.3) | 12.0 (10.0, 29.0)* |
| Asthma control test (ACT) score | 20 (19, 23) | NA |
| Asthma control questionnaire-7 (ACQ-7) score | 0.7 (0.6, 1.0) | NA |
| Medication status | ||
| Short-acting beta-2 agonist (SABA) | 3 | 0 |
| Long-acting beta-2 agonist (LABA) | 0 | 0 |
| Long-acting muscarinic antagonist (LAMA) | 0 | 0 |
| LABA + inhaled corticosteroid (ICS) | 1 | 0 |
| LAMA + ICS | 7 | 0 |
| Theophylline | 1 | 0 |
Data are presented as the median (interquartile range) unless otherwise stated
*P < 0.05; **P < 0.01 ***P < 0.001
Fig. 1Differential expression of lncRNAs and mRNAs in patients with asthma. Volcano plots are used to distinguish between differentially expressed lncRNAs (A) and mRNAs (B). Red and blue indicate up- and down-regulation, respectively. Hierarchical clustering analysis of dysregulated lncRNAs (C) and mRNAs (D). Relative lncRNA or mRNA expression is depicted according to the color scale. Red indicates elevated expression and blue indicates reduced expression
Fig. 2GO and KEGG pathway analyses. GO analysis of significantly upregulated (A) and downregulated (B) mRNAs clustered in the BP. KEGG pathways analysis of differentially upregulated (C) and downregulated mRNAs (D). The abscissa shows ‐LogP, and the ordinate shows GO terms or KEGG pathways. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process
Fig. 3Global signal transduction network analysis of asthma mRNAs. In the constructed network, nodes represent mRNAs, the size of the node’s area represents the value of the degree, and red indicates up-regulation and blue indicates down-regulation. The nodes are connected by an edge. The acronyms a, b, c, p, inh, and ind (e) indicate activation, binding, compound, phosphorylation, inhibition, and indirect effect, respectively
Core mRNAs selected using the gene–gene functional interaction network
| Gene symbol | Style | Betweenness centrality | Degree |
|---|---|---|---|
| Up | 0.052151 | 35 | |
| Down | 0 | 32 | |
| Down | 0.033763 | 29 | |
| Down | 0.04064 | 24 | |
| Up | 0.02381 | 23 | |
| Down | 0.0408 | 21 | |
| Down | 0.030527 | 20 | |
| Up | 0.040001 | 19 | |
| Down | 0.026864 | 18 | |
| Down | 0.026311 | 18 | |
| Down | 0.011193 | 18 | |
| Down | 0.024722 | 17 | |
| Down | 0.019986 | 17 | |
| Down | 0.014337 | 16 | |
| Down | 0.014575 | 12 | |
| Down | 0.013518 | 12 | |
| Down | 0.006587 | 12 | |
| Down | 0.005553 | 12 | |
| Down | 0.006042 | 11 | |
| Down | 0.00833 | 11 |
Betweenness centrality ≥ 0.005. Betweenness centrality is an indicator of a gene’s centrality in a network. It is equal to the number of shortest paths from all vertices to all others that pass through that gene. The degree of a gene was defined as the number of directly linked genes within a network
Correlation between lncRNAs and core mRNAs
| mRNA | lncRNA | Pearson’s correlation | Regulation |
|---|---|---|---|
| NONHSAT115963 | 0.917** | Positive | |
| AC019050.1 | − 0.925** | Negative | |
| MTCYBP3 | 0.925** | Positive | |
| KB-67B5.12 | 0.935** | Positive | |
| HNRNPA1P12 | − 0.901** | Negative |
**P < 0.01
Fig. 4RT‐qPCR validation of selected mRNAs and lncRNAs. A Relative expression levels of the mRNAs and lncRNAs between the patients with asthma and healthy control assessed by RT-qPCR. The y-axis represents the relative expression (2−ΔΔCT). Data are presented as the median (interquartile range). All data were normalized to GAPDH expression. B Comparison of mean fold-changes between microarray data and RT-qPCR results. **P < 0.01; ***P < 0.001; **** P < 0.0001; ns, no significance. RT-qPCR, real-time quantitative polymerase chain reaction